Literature DB >> 33282100

Pipeline Perspectives and Therapy Updates.

James Q Del Rosso1.   

Abstract

Year:  2020        PMID： 33282100      PMCID： PMC7716736     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN： 1941-2789


× No keyword cloud information.
  17 in total

1.  Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid.

Authors:  Alex Kaye; Samantha C Gordon; Sandhya C Deverapalli; Min Ji Her; David Rosmarin
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

2.  Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review.

Authors:  Aleksi J Hendricks; Gil Yosipovitch; Vivian Y Shi
Journal:  J Dermatolog Treat       Date:  2019-11-12       Impact factor: 3.359

3.  Dupilumab for the treatment of dyshidrotic eczema in 15 consecutive patients.

Authors:  Reid A Waldman; Madeline E DeWane; Brett Sloan; Jane M Grant-Kels; Jun Lu
Journal:  J Am Acad Dermatol       Date:  2020-01-08       Impact factor: 11.527

4.  Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis

Authors:  Nolan J. Maloney; Kyle Tegtmeyer; Jeffrey Zhao; Scott Worswick
Journal:  J Drugs Dermatol       Date:  2019-10-01       Impact factor: 2.114

5.  Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Phenotype of Adult Atopic Dermatitis.

Authors:  Maddalena Napolitano; Gabriella Fabbrocini; Massimiliano Scalvenzi; Steven Paul Nisticò; Stefano Dastoli; Cataldo Patruno
Journal:  Dermatitis       Date:  2020-01-03       Impact factor: 4.845

6.  Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo.

Authors:  Andrea Chiricozzi; Martina Maurelli; Niccolò Gori; Giuseppe Argenziano; Clara De Simone; Giulia Calabrese; Giampiero Girolomoni; Ketty Peris
Journal:  J Am Acad Dermatol       Date:  2020-03-27       Impact factor: 11.527

Review 7.  Adult-Onset Atopic Dermatitis: Fact or Fancy?

Authors:  Jon M Hanifin
Journal:  Dermatol Clin       Date:  2017-07       Impact factor: 3.478

8.  Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients.

Authors:  A Calugareanu; M Jachiet; M Tauber; A Nosbaum; F Aubin; L Misery; C Droitcourt; S Barbarot; S Debarbieux; A Saussine; M Bagot; A de Masson; J Sénéschal; D Staumont-Sallé; J-D Bouaziz
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-10-17       Impact factor: 6.166

9.  Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.

Authors:  Sophie Glatt; Dominique Baeten; Terry Baker; Meryn Griffiths; Lucian Ionescu; Alastair D G Lawson; Ash Maroof; Ruth Oliver; Serghei Popa; Foteini Strimenopoulou; Pavan Vajjah; Mark I L Watling; Nataliya Yeremenko; Pierre Miossec; Stevan Shaw
Journal:  Ann Rheum Dis       Date:  2017-12-23       Impact factor: 19.103

Review 10.  The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond.

Authors:  Nicolo Costantino Brembilla; Luisa Senra; Wolf-Henning Boehncke
Journal:  Front Immunol       Date:  2018-08-02       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.